ECTRIMS 2019 - MSBase presentations
Oral Presentations
Liesbet Peeters, Rehabilitation and MS-Centre Overpelt, Belgium
Introducing machine learning for full MS patient trajectories improves predictions for disability score progression
Sifat Sharmin, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Predicting long-term sustained disability progression in multiple sclerosis
Poster Presentations
Ilya Kister, New York University School of Medicine, USA
Does Multiple Sclerosis Severity Score (MSSS) provide additional prognostic value to the ‘MSBase model’ of individual treatment response in Multiple Sclerosis
Helmut Butzkueven, MSBase collaboration with Merck
Real-world experience with Cladribine in MSBase registry
Charles Malpas, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Disease reactivation following fingolimod cessation
Nahid Moradi, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
MS cohorts and treatment utilization in academic centres in the Middle East
Helmut Butzkueven, MSBase collaboration with Roche
Real-world experience with Ocrelizumab in MSBase registry
Izanne Roos, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis
Therapeutic Lag in Relapsing Multiple Sclerosis
Charles Malpas, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Aggressive form of multiple sclerosis can be predicted early after disease onset
Sifat Sharmin, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
Francesca Bovis, MSBase fellow, supervised by Claudio Solaro, Centro Sclerosi Multipla ASL3 Genovese, Italy
Personalizing treatment effect based on patient’s baseline profile: A statistical modelling approach applied to randomized clinical trial and observational study data
Tomas Kalincik, The Royal Melbourne Hospital, Australia
Modifiers of the effectiveness of MS immunotherapies
Tomas Uher, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia
Disability trajectories in relapsing-remitting multiple sclerosis (ePoster)
Back